- Page 1 and 2:
Rivaroxaban for the treatment of de
- Page 3 and 4:
TABLE OF CONTENTS List of Abbreviat
- Page 5 and 6:
Table 12 Time to therapeutic INR (I
- Page 7 and 8:
identified in the model). Table 40
- Page 9 and 10:
Figures Figure 1 Flow diagram for i
- Page 11 and 12:
Figure 23 Exploratory analysis in c
- Page 13 and 14:
MS Manufacturer’s submission NE S
- Page 15 and 16:
The dose of LMWH used reflects Amer
- Page 17 and 18:
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
- Page 19 and 20:
The exploratory analysis in cancer
- Page 21 and 22:
intended treatment duration of 12 m
- Page 23 and 24:
VTE therefore has a substantial bur
- Page 25 and 26:
indefinite treatment. VTE LMWH, low
- Page 27 and 28:
3 Critique of manufacturer’s defi
- Page 29 and 30:
Subgroups to be considered Special
- Page 31 and 32:
contraindications for the drug (as
- Page 33 and 34:
3.1.3 MTC populations The populatio
- Page 35 and 36:
3.2.2 Length of treatment As discus
- Page 37 and 38:
“No preventative therapy” is th
- Page 39 and 40:
It could be argued that poor TTR ma
- Page 41 and 42:
3.4.2 Outcomes recommended by EMA r
- Page 43 and 44:
4 CLINICAL EFFECTIVENESS 4.1 Critiq
- Page 45 and 46:
competitor products were excluded f
- Page 47 and 48:
Figure 1 Flow diagram for identifyi
- Page 49 and 50:
Table 7: Table showing list of rele
- Page 51 and 52:
The approach taken to quality asses
- Page 53 and 54:
o EINSTEIN-DVT dose-ranging study 3
- Page 55 and 56:
Trial name References, study type E
- Page 57 and 58:
4.2.1 Critique of pivotal EINSTEIN-
- Page 59 and 60:
However, the study design did not i
- Page 61 and 62:
Table 10: Summary of outcomes for E
- Page 63 and 64:
Chi-square analyses were undertaken
- Page 65 and 66:
clarification on this matter, the m
- Page 67 and 68:
Both of these factors are likely to
- Page 69 and 70:
It remains unclear why these patien
- Page 71 and 72:
leeding may be less suited to longe
- Page 73 and 74:
may account for the apparent differ
- Page 75 and 76:
Table 13: Criteria used to define a
- Page 77 and 78:
DVT and/or PE xxxxxxxxx xxxxxxxxxxx
- Page 79 and 80:
There is some doubt about the appro
- Page 81 and 82:
Subgroup analyses - EINSTEIN-Ext Su
- Page 83 and 84:
o It is clear that bleed events wer
- Page 85 and 86:
is likely to be small as the outcom
- Page 87 and 88:
depends on the specific parameteris
- Page 89 and 90:
4.4.3 Between study standard deviat
- Page 91 and 92:
Table 19.2: VTE recurrence (dichoto
- Page 93 and 94:
Table 22 Uncertainties in clinical
- Page 95 and 96:
The ERG are of the understanding th
- Page 97 and 98:
For the primary analysis, the rates
- Page 99 and 100:
In the economic model, the manufact
- Page 101 and 102:
Finally, in cancer patients, the ma
- Page 103 and 104:
Our experts believed that patients
- Page 105 and 106: Similarly, the manufacturer used da
- Page 107 and 108: Table 25: baseline risk of events f
- Page 109 and 110: y intended treatment duration given
- Page 111 and 112: eflect the current long term risk o
- Page 113 and 114: survival of 70% in the 148 non-surg
- Page 115 and 116: Monitoring xxxxxxxxxxxxxxxxxxxxxxxx
- Page 117 and 118: The ERG acknowledges that the monit
- Page 119 and 120: For patients managed in the inpatie
- Page 121 and 122: The searches identified 2,811 poten
- Page 123 and 124: The health state utility value for
- Page 125 and 126: xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx
- Page 127 and 128: few occasions for both VTEs and ble
- Page 129 and 130: 2) the values used in the PSA for t
- Page 131 and 132: 5.2.1 Results included in the manuf
- Page 133 and 134: Figure 8: Tornado plot - Net Moneta
- Page 135 and 136: 5.2.2.1.2. Results for patients for
- Page 137 and 138: Figure 12: Cost-effectiveness plane
- Page 139 and 140: Figure 14: Tornado plot - Net Monet
- Page 141 and 142: 5.2.2.2 Subgroup analysis - cancer
- Page 143 and 144: Figure 17: Tornado plot - Net Monet
- Page 145 and 146: 5.2.3 Comment on validity of result
- Page 147 and 148: Table 36: Summary of uncertainties
- Page 149 and 150: Summary of uncertainties Has the im
- Page 151 and 152: Summary of uncertainties Has the im
- Page 153 and 154: Summary of uncertainties Has the im
- Page 155: Superseded - See Erratum 6. ADDITIO
- Page 159 and 160: Superseded - See Erratum Table 38:
- Page 161 and 162: Superseded - See Erratum Table 42:
- Page 163 and 164: Superseded - See Erratum Figure 21:
- Page 165 and 166: Superseded - See Erratum Table 46:
- Page 167 and 168: Superseded - See Erratum 6.3. Proba
- Page 169 and 170: Superseded - See Erratum Table 50:
- Page 171 and 172: Superseded - See Erratum Table 54:
- Page 173 and 174: 6.5. Exploratory analysis in cancer
- Page 175 and 176: Figure 23: Exploratory analysis in
- Page 177 and 178: Table 60: Deterministic base case a
- Page 179 and 180: The ERG also examined the impact of
- Page 181 and 182: days after stopping treatment.(Bull
- Page 183 and 184: Both Phase II studies performed ana
- Page 185 and 186: Appendix 2 Correction of Tables 29
- Page 187 and 188: Appendix 3 Definition of `sufficien
- Page 189 and 190: A bullet on page 42 states that `53
- Page 191 and 192: Both numbers refer to the placebo a
- Page 193 and 194: 9. REFERENCES 1. Bayer PLC. Rivarox
- Page 195 and 196: http://www.dh.gov.uk/en/Publication
- Page 197 and 198: 51. Department of Health. NHS Refer
- Page 199: 77. NICE Guidance. Atrial fibrillat